Best Practices for 18F-Fluciclovine PET/CT Imaging of Recurrent Prostate Cancer: A Guide for Technologists

Funmilayo I Tade; Rebecca A Sajdak; Mehdat Gabriel; Robert H Wagner; Bital Savir-Baruch

doi:10.2967/jnmt.119.227116

Best Practices for ¹⁸F-Fluciclovine PET/CT Imaging of Recurrent Prostate Cancer: A Guide for Technologists

J Nucl Med Technol. 2019 Dec;47(4):282-287. doi: 10.2967/jnmt.119.227116. Epub 2019 Jun 10.

Authors

Funmilayo I Tade¹, Rebecca A Sajdak¹, Mehdat Gabriel¹, Robert H Wagner¹, Bital Savir-Baruch²

Affiliations

¹ Division of Nuclear Medicine, Department of Radiology, Loyola University Medical Center, Maywood, Illinois.
² Division of Nuclear Medicine, Department of Radiology, Loyola University Medical Center, Maywood, Illinois bital.savir-baruch@lumc.edu.

PMID: 31182661
DOI: 10.2967/jnmt.119.227116

Abstract

¹⁸F-fluciclovine is a Food and Drug Administration-approved PET tracer indicated for patients suspected to have recurrent prostate cancer based on a prostate-specific antigen rise after prior therapy. ¹⁸F-fluciclovine PET/CT is performed significantly differently from ¹⁸F-FDG PET/CT and requires special attention to patient preparation, injection technique, and imaging time. This article aims to provide nuclear medicine technologists with the best-practice guidelines for the ¹⁸F-fluciclovine PET/CT protocol.

Keywords: Axumin; FACBC; PET/CT; fluciclovine; prostate cancer.

MeSH terms

Carboxylic Acids*
Cyclobutanes*
Guidelines as Topic*
Humans
Male
Patient Positioning
Positron Emission Tomography Computed Tomography / methods*
Prostatic Neoplasms / diagnostic imaging*
Recurrence

Substances

Carboxylic Acids
Cyclobutanes
fluciclovine F-18